Bambusa Therapeutics Announces First Subject Dosed in Phase 1 Clinical Trial of BBT002, A Novel Platform-In-A-Molecule Bispecific Antibody for Broad I&I Conditions and U.S. FDA Clearance of IND Application for BBT001 ...Middle East

Preclinical data with BBT002 demonstrate its best-in-disease potential for improved efficacy and dosing convenience across respiratory, dermatology, and gastroenterology indications Interim safety and pharmacokinetic data from BBT002-01 study anticipated in Q1 2026 The clearance of...

Read More Details
Finally We wish PressBee provided you with enough information of ( Bambusa Therapeutics Announces First Subject Dosed in Phase 1 Clinical Trial of BBT002, A Novel Platform-In-A-Molecule Bispecific Antibody for Broad I&I Conditions and U.S. FDA Clearance of IND Application for BBT001 )

Also on site :

• The Diet That Helped a ’90s Pop Star Reclaim His Life
• Hollywood Hunk, 27, Is Unrecognizable After Dramatic Transformation
• Aid ship aiming to break Israel’s siege of Gaza sets sail from Italy